AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06458179 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-guided proximal greater occipital nerve radiofrequency ablation
Description: In the prone position with the head slightly flexed and the US probe was placed in the neck transversely and then was located the bifid spinous process of C2 and the probe was lateralized (toward the affected side). At this level, the GON is located above the obliquus capitis inferior muscle and deeper than the semispinalis capitis muscle. The in-plane approach from medial to lateral was employed to treat the nerve with a 21 G 5-mm active tip radiofrequency needle. Sensory stimulation was administered at 50 Hz for 1 ms to induce paresthesia, pain, or irritation. A motor stimulus was applied at 2 Hz for 1 ms and up to 2 volts to see if fasciculation was absent. Then 1 mL of 2% lidocaine was administered through the RF cannulas to alleviate procedure related pain. Conventional RFA was conducted for 60 seconds at a temperature of 60 degrees. Following the procedure, 2 mg of dexamethasone was administered per lesion site.
Study NCT04752072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Skills Training in Affective and Interpersonal Regulation
Description: The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions.
Study NCT04752072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
Study NCT06237660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Forced oscillation technique (FOT)
Description: Breathing test will be performed using forced oscillation technique (FOT), to see how the child's lungs work and to detect airway inflammation. The test will be explained to the child and completed using our established protocols. This test will only require the child to breathe in and out normally, and therefore can be done in preschool aged children. The current test that is used to check lung function called spirometry cannot be used in preschool children, as it involves following complicated instructions. The aim is to assess how well this newer lung function test is tolerated, in children aged 1-5 years.
Study NCT06237660 — intervention group
Intervention type: PROCEDURE
Intervention: Sputum induction
Description: Sputum induction is a test of obtaining phlegm after inhalation of salt water mist (saline nebuliser) and this will allow the research team to look for any relationships between infection in the lungs and the accuracy of the less invasive, nose and throat swabs. The research team will obtain phlegm samples, with a quick suction after patients have inhaled the salty mist (saline nebuliser) which will help loosen up their phlegm. If the child can cough it up, they will be encouraged to do it.
Study NCT06237660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal swab
Description: Swabs from children's nose and throats (similar to swab tests that are done for Covid tests), that will be used to test for bacterial infection
Study NCT05268900 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Volume control ventilation group
Description: Volume control ventilation mode
Study NCT04839692 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyaluronic acid filler
Description: Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
Study NCT05180357 — intervention group
Intervention type: OTHER
Intervention: FASENRA(benralizumab)
Description: This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
Study NCT05713981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian gland (MG) expression
Description: The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
Study NCT05684445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distant reiki group
Description: According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
Study NCT05268900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure control ventilation-volume guaranteed group
Description: Pressure control ventilation-volume guaranteed mode
Study NCT05074160 — intervention group
Intervention type: DEVICE
Intervention: OCS Liver
Description: Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
Study NCT04939909 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum toxin type A
Description: Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
Study NCT05083962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Program
Description: An intensive behavior change curriculum designed to help create and sustain healthy habits
Study NCT05521386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Single pill in an acute dose of 5 mg per kg of body mass
Study NCT05521386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single pill in an acute dose of 5 mg per kg of body mass
Study NCT04759833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride oral solution or oral tablets.
Study NCT05747768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin
Description: Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
Study NCT04901390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with B. lactis and added cane sugar
Description: The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
Study NCT06326359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous stromal vascular fraction
Description: autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
Study NCT04759833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prucalopride-matching placebo oral solution or oral tablets.
Study NCT04610320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab-SC
Description: >Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
Study NCT05533294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-RAGE Injection
Description: ARO-RAGE injection for sc administration
Study NCT05533294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline (0.9% NaCl) by sc injection
Study NCT05471492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Product
Description: PF-06480605 150 mg
Study NCT05471492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05180916 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVNS
Description: Cerbomed NEMOS
Study NCT05303636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
Description: LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
Study NCT06128889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program
Description: The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
Study NCT06111352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralidoxime
Description: Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
Study NCT06111352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
Study NCT06111352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atropine
Description: Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
Study NCT05310695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSAC - rapid
Description: NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.
Study NCT05310695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSAC - ordinary
Description: NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.
Study NCT05310695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSAC - active control
Description: The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
Study NCT06163391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOT201
Description: intravenous infusion
Study NCT03987802 — intervention group
Intervention type: DRUG
Intervention: Faster-acting insulin aspart
Description: Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
Study NCT04918290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm Eye Tape
Description: Eye tape to protect the eye from corneal abrasions during surgery.
Study NCT04918290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpore Eye Tape
Description: Eye tape to protect the eye from corneal abrasions during surgery.
Study NCT05285215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated psychological program (IPP)
Description: Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted.
Study NCT04699838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study NCT04699838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT04699838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide
Study NCT04620993 — intervention group
Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of plantar fascia
Description: The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position.
Study NCT04620993 — intervention group
Intervention type: OTHER
Intervention: Evaluation of navıcular drop
Description: The amount of navicular drop of both feet will be measured
Study NCT04620993 — intervention group
Intervention type: OTHER
Intervention: Evaluation of plantar pressure distrubution
Description: The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
Study NCT04790331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
Study NCT04790331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina.
Study NCT04790331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablet
Study NCT06509243 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tablets Acarizax
Description: sublingual immunotherapy to house dust mites
Study NCT04699838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab
Study NCT04699838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib
Study NCT04620772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide vs placebo
Study NCT04620772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide vs placebo
Study NCT06509243 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dupilumab
Description: dupilumab - biologic therapy for atopic dermatitis
Study NCT06509243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine used in atopic dermatitis
Study NCT06481605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-REX
Description: The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
Study NCT04542395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing Willingness and Uptake of COVID-19 Testing and Vaccination
Description: Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
Study NCT05424744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Management of Hypertension
Description: Telemedicine Management of high blood pressure using home blood pressure monitoring and telemedicine based hypertension self- management support and pharmacotherapy. This will be supplemented by support from community health workers.
Study NCT05392101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox 360 MG
Description: Deferasirox 360 MG p.o. once daily
Study NCT05749276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darzalex
Description: DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)
Study NCT05760651 — intervention group
Intervention type: OTHER
Intervention: Patient Participation Form
Description: A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale
Study NCT05760651 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Timed up - and - go test
Description: . The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.